CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade Edwards Lifesciences - EW CFD

78.04
0.03%
0.22
Low: 77.59
High: 78.68
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.22
Long position overnight fee

Long position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Edwards Lifesciences Corp ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 78.06
Open* 77.59
1-Year Change* -28.28%
Day's Range* 77.59 - 78.68
52 wk Range 67.13-131.10
Average Volume (10 days) 2.71M
Average Volume (3 months) 104.69M
Market Cap 48.35B
P/E Ratio 33.67
Shares Outstanding 618.26M
Revenue 5.36B
EPS 2.32
Dividend (Yield %) N/A
Beta 1.01
Next Earnings Date Jan 31, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 27, 2023 78.04 -0.05 -0.06% 78.09 78.75 77.59
Jan 26, 2023 78.06 0.41 0.53% 77.65 78.39 77.12
Jan 25, 2023 77.59 1.68 2.21% 75.91 77.64 75.43
Jan 24, 2023 77.02 -1.99 -2.52% 79.01 79.61 76.91
Jan 23, 2023 79.95 1.02 1.29% 78.93 80.68 78.74
Jan 20, 2023 79.21 0.35 0.44% 78.86 79.25 77.54
Jan 19, 2023 78.34 0.96 1.24% 77.38 78.83 77.15
Jan 18, 2023 78.19 -0.59 -0.75% 78.78 79.34 78.02
Jan 17, 2023 78.72 1.01 1.30% 77.71 78.88 77.31
Jan 13, 2023 78.16 1.41 1.84% 76.75 78.32 76.75
Jan 12, 2023 77.60 0.52 0.67% 77.08 78.15 76.03
Jan 11, 2023 77.56 0.57 0.74% 76.99 78.38 76.55
Jan 10, 2023 76.92 0.93 1.22% 75.99 77.43 75.67
Jan 9, 2023 76.26 -0.70 -0.91% 76.96 78.15 76.21
Jan 6, 2023 76.86 2.00 2.67% 74.86 77.04 73.79
Jan 5, 2023 75.07 -0.28 -0.37% 75.35 76.35 74.90
Jan 4, 2023 76.36 1.52 2.03% 74.84 76.44 74.02
Jan 3, 2023 74.14 -0.94 -1.25% 75.08 76.74 73.72
Dec 30, 2022 74.48 0.28 0.38% 74.20 74.57 73.26
Dec 29, 2022 75.09 1.69 2.30% 73.40 75.34 72.76

Edwards Lifesciences Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 2963.7 3435.3 3722.8 4348 4386.3 5232.5
Revenue 2963.7 3435.3 3722.8 4348 4386.3 5232.5
Cost of Revenue, Total 797.4 875.3 939.4 1114.4 1080.6 1248.9
Gross Profit 2166.3 2560 2783.4 3233.6 3305.7 3983.6
Total Operating Expense 2225.8 2400.4 2967.5 3201.2 3488.7 3542.2
Selling/General/Admin. Expenses, Total 904.7 985.8 1088.5 1240.2 1228.4 1493.7
Research & Development 443.3 552.6 622.2 752.7 760.7 903.1
Interest Expense (Income) - Net Operating 8.7 -1.6
Unusual Expense (Income) 67.1 -13.4 323.1 100 405.4 20.6
Other Operating Expenses, Total 4.6 1.7 -5.7 -6.1 13.6 -124.1
Operating Income 737.9 1034.9 755.3 1146.8 897.6 1690.3
Net Income Before Taxes 737.9 1034.9 761.4 1166.5 916.7 1702
Net Income After Taxes 569.5 877.7 738 1049.7 823.4 1503.1
Net Income Before Extra. Items 569.5 877.7 738 1049.7 823.4 1503.1
Net Income 569.5 583.6 722.2 1046.9 823.4 1503.1
Income Available to Common Excl. Extra. Items 569.5 877.7 738 1049.7 823.4 1503.1
Income Available to Common Incl. Extra. Items 569.5 583.6 722.2 1046.9 823.4 1503.1
Diluted Net Income 569.5 583.6 722.2 1046.9 823.4 1503.1
Diluted Weighted Average Shares 653.407 647.706 640.806 636.606 631.9 631.2
Diluted EPS Excluding Extraordinary Items 0.87159 1.35509 1.15167 1.6489 1.30305 2.38134
Diluted Normalized EPS 0.95084 1.33754 1.64039 1.79025 1.87932 2.41016
Total Extraordinary Items -294.1 -15.8 -2.8
Interest Income (Expense), Net Non-Operating 17.3 21.3 20.5 9.8
Other, Net -11.2 -1.6 -1.4 1.9
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 1216.6 1376 1310.2 1329.7 1341.2
Revenue 1216.6 1376 1310.2 1329.7 1341.2
Cost of Revenue, Total 293.4 334.3 311.7 309.5 299.3
Gross Profit 923.2 1041.7 998.5 1020.2 1041.9
Total Operating Expense 833.1 833.9 919.9 955.3 902.4
Selling/General/Admin. Expenses, Total 330.8 374.5 364.4 424 370.3
Research & Development 207 225.3 238 232.8 228.6
Unusual Expense (Income) 6.4 2.4 4.7 7.1 7.1
Other Operating Expenses, Total -4.5 -102.6 1.1 -18.1 -2.9
Operating Income 383.5 542.1 390.3 374.4 438.8
Interest Income (Expense), Net Non-Operating 4.7 3.1 0.4 1.6 -4
Other, Net 1.1 0.3 0.2 0.3 1.3
Net Income Before Taxes 389.3 545.5 390.9 376.3 436.1
Net Income After Taxes 338.2 489.5 340.1 335.3 373.6
Net Income Before Extra. Items 338.2 489.5 340.1 335.3 373.6
Net Income 338.2 489.5 340.1 335.3 373.6
Income Available to Common Excl. Extra. Items 338.2 489.5 340.1 335.3 373.6
Income Available to Common Incl. Extra. Items 338.2 489.5 340.1 335.3 373.6
Diluted Net Income 338.2 489.5 340.1 335.3 373.6
Diluted Weighted Average Shares 631.3 629.9 631.7 631.8 629.4
Diluted EPS Excluding Extraordinary Items 0.53572 0.77711 0.53839 0.53071 0.59358
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.54453 0.78053 0.54486 0.54072 0.60325
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 2240 2549.2 2286.9 2984 3091 3180.7
Cash and Short Term Investments 1271.1 1337.5 956.5 1516.9 1402.6 1466.8
Cash & Equivalents 930.1 818.3 714.1 1179.1 1183.2 862.8
Short Term Investments 341 519.2 242.4 337.8 219.4 604
Total Receivables, Net 414.6 479.3 537.3 599.1 602.8 664.9
Accounts Receivable - Trade, Net 414.6 438.7 456.9 543.6 514.6 582.2
Total Inventory 396.6 554.9 607 640.9 802.3 726.7
Prepaid Expenses 45.9 60.6 54.3 59.1 75.1 85.2
Other Current Assets, Total 111.8 116.9 131.8 168 208.2 237.1
Total Assets 4510 5666.4 5323.7 6488.1 7237.1 8502.6
Property/Plant/Equipment, Total - Net 580 679.7 867.5 1140.4 1489.4 1638.7
Goodwill, Net 626.1 1126.5 1112.2 1167.7 1173.2 1167.9
Intangibles, Net 204.8 468 343.2 336.5 331.4 323.6
Long Term Investments 532.1 567 506.3 585.5 801.6 1834.2
Other Long Term Assets, Total 327 276 207.6 274 350.5 357.5
Total Current Liabilities 532.5 1420 876.6 902.4 893.9 1032.3
Accounts Payable 97.1 116.6 134 180.4 196.5 204.5
Accrued Expenses 418.4 516.1 510.2 642.7 578.7 714.2
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 17 189.3 232.4 79.3 118.7 113.6
Total Liabilities 1891 2710.2 2183.3 2339.8 2662.8 2666.7
Total Long Term Debt 822.3 438.4 593.8 594.4 595 595.7
Long Term Debt 822.3 438.4 593.8 594.4 595 595.7
Other Liabilities, Total 536.2 851.8 588 671.3 959.5 779.7
Total Equity 2619 2956.2 3140.4 4148.3 4574.3 5835.9
Preferred Stock - Non Redeemable, Net 0 0 0 0 0 0
Common Stock 242.6 212 215.2 218.1 636.4 642
Additional Paid-In Capital 1167.8 1166.9 1384.4 1623.3 1438.1 1700.4
Retained Earnings (Accumulated Deficit) 3906.3 1962.1 2694.7 3741.6 4565 6068.1
Treasury Stock - Common -2499.3 -252.1 -1015.4 -1278.7 -1904.1 -2416.9
Other Equity, Total -198.4 -128.1 -133.5 -157.7 -169.7 -150.8
Total Liabilities & Shareholders’ Equity 4510 5666.4 5323.7 6488.1 7237.1 8502.6
Total Common Shares Outstanding 634.806 629.106 623.106 627.306 624.3 624.1
Current Port. of LT Debt/Capital Leases 598 0 0 0
Unrealized Gain (Loss) -4.6 -5 1.7 8.6 -6.9
Property/Plant/Equipment, Total - Gross 1322.8 1652.7 2087.9 2293.3
Accumulated Depreciation, Total -455.3 -512.3 -598.5 -654.6
Deferred Income Tax 124.9 171.7 214.4 259
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 3069.2 3322.9 3515.5 3180.7 3241.3
Cash and Short Term Investments 1330.6 1561.2 1794.7 1466.8 1495.9
Cash & Equivalents 1174.2 1312.8 1506.9 862.8 1030.9
Short Term Investments 156.4 248.4 287.8 604 465
Total Receivables, Net 664.3 700.3 664.2 664.9 686.2
Accounts Receivable - Trade, Net 586.6 640.5 600.6 582.2 636.3
Total Inventory 767.9 759.5 737.8 726.7 730.6
Prepaid Expenses 77.3 68.6 76.9 85.2 94.1
Other Current Assets, Total 229.1 233.3 241.9 237.1 234.5
Total Assets 7213.7 7662.1 8160.3 8502.6 8419.9
Property/Plant/Equipment, Total - Net 1506.4 1530.4 1549.4 1638.7 1642.3
Goodwill, Net 1170.8 1171.8 1170.4 1167.9 1166.3
Intangibles, Net 330.3 327 325.3 323.6 322
Long Term Investments 802.2 1014.2 1282 1834.2 1623.7
Other Long Term Assets, Total 334.8 295.8 317.7 357.5 424.3
Total Current Liabilities 799 886.2 966.5 1032.3 949.9
Accounts Payable 150.4 144.6 139.5 204.5 158.8
Accrued Expenses 546.9 634.7 721.7 714.2 615.9
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 101.7 106.9 105.3 113.6 175.2
Total Liabilities 2555.3 2528.8 2619 2666.7 2575
Total Long Term Debt 595.2 595.4 595.5 595.7 595.9
Long Term Debt 595.2 595.4 595.5 595.7 595.9
Deferred Income Tax 224.2 234.2 245.4 259 270.7
Other Liabilities, Total 936.9 813 811.6 779.7 758.5
Total Equity 4658.4 5133.3 5541.3 5835.9 5844.9
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 637.5 640.1 641.2 642 642.9
Additional Paid-In Capital 1496.8 1578.7 1643.1 1700.4 1769.4
Retained Earnings (Accumulated Deficit) 4903.2 5392.7 5732.8 6068.1 6441.7
Treasury Stock - Common -2206.7 -2318.6 -2320.4 -2416.9 -2822.5
Unrealized Gain (Loss) 4.7 4.8 3 -6.9 -39.2
Other Equity, Total -177.1 -164.4 -158.4 -150.8 -147.4
Total Liabilities & Shareholders’ Equity 7213.7 7662.1 8160.3 8502.6 8419.9
Total Common Shares Outstanding 621.8 623.1 624.2 624.1 621.4
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line 569.5 583.6 722.2 1046.9 823.4 1503.1
Cash From Operating Activities 704.4 1000.7 926.8 1179.4 1054.3 1732.1
Cash From Operating Activities 71.2 81.9 77.4 89.3 107.2 134.8
Deferred Taxes -37.4 17.8 -27.3 12.1 -49.4 -41.4
Non-Cash Items 35 83.2 197.1 235.4 130.9 -9.7
Cash Taxes Paid 99.9 143.7 223.7 61.5 197.9 182.5
Cash Interest Paid 16.1 19.9 30.1 19.9 19.9 20.2
Changes in Working Capital 66.1 234.2 -42.6 -204.3 42.2 145.3
Cash From Investing Activities -211.7 -647.2 76.7 -595.8 -531.1 -1722.5
Capital Expenditures -217.4 -175.5 -241.7 -278.4 -407.3 -329.8
Other Investing Cash Flow Items, Total 5.7 -471.7 318.4 -317.4 -123.8 -1392.7
Cash From Financing Activities -268.5 -473.2 -1101.2 -115.6 -486.9 -356.3
Financing Cash Flow Items 68.4 0 -15.4 -2.8 -1.2 -0.3
Issuance (Retirement) of Stock, Net -559 -649.5 -648.5 -102.8 -484.9 -354.2
Issuance (Retirement) of Debt, Net 222.1 176.3 -437.3 -10 -0.8 -1.8
Foreign Exchange Effects -12.5 7.9 -6.5 -3 -20.5 13.9
Net Change in Cash 211.7 -111.8 -104.2 465 15.8 -332.8
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 338.2 827.7 1167.8 1503.1 373.6
Cash From Operating Activities 300.5 826.6 1358.5 1732.1 293.3
Cash From Operating Activities 32.4 68.2 101.8 134.8 34.7
Deferred Taxes 10.8 16.2 20.1 -41.4 -42.6
Non-Cash Items 28.3 -47.5 -15.8 -9.7 57
Changes in Working Capital -109.2 -38 84.6 145.3 -129.4
Cash From Investing Activities -49.7 -379.2 -756.6 -1722.5 229.5
Capital Expenditures -106 -175.3 -236 -329.8 -72.7
Other Investing Cash Flow Items, Total 56.3 -203.9 -520.6 -1392.7 302.2
Cash From Financing Activities -274.3 -333.3 -294.3 -356.3 -368.1
Financing Cash Flow Items -2.9 -3 -1 -0.3 0
Issuance (Retirement) of Stock, Net -271 -328.7 -291.6 -354.2 -368.1
Issuance (Retirement) of Debt, Net -0.4 -1.6 -1.7 -1.8 0
Foreign Exchange Effects 14.2 11.6 12.1 13.9 13.2
Net Change in Cash -9.3 125.7 319.7 -332.8 167.9
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.1891 50629906 601760 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.113 31611698 -370907 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.3359 26807322 -90807 2022-09-30 LOW
Capital International Investors Investment Advisor 3.6712 22697460 293568 2022-09-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 2.7849 17217652 819288 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.3691 14647117 468181 2022-09-30 LOW
Brown Advisory Investment Advisor/Hedge Fund 2.3009 14225834 423457 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9297 11930529 199365 2022-09-30 LOW
Walter Scott & Partners Ltd. Investment Advisor/Hedge Fund 1.8866 11664308 -1145504 2022-09-30 LOW
Sands Capital Management, LLC Investment Advisor 1.6831 10405902 -1305885 2022-09-30 LOW
Fisher Investments Investment Advisor/Hedge Fund 1.2193 7538738 208057 2022-09-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 1.1967 7398732 -543403 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.0615 6562640 -2208605 2022-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.0484 6481823 -233773 2021-12-31 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.9106 5629834 -173381 2022-09-30 LOW
Nuveen LLC Pension Fund 0.8796 5438247 -1014525 2022-09-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.8792 5435848 -1010885 2022-09-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7709 4766457 -217735 2022-09-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 0.723 4469833 -657987 2022-09-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7027 4344513 -90711 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Profit/Loss

Edwards Lifesciences Company profile

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Edwards Lifesciences Corp revenues increased 19% to $5.23B. Net income increased 83% to $1.5B. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 20% to $3.42B, Surgical Heart Valve Therapy segment increase of 17% to $889.1M, Critical Care segment increase of 15% to $834.9M, United States segment increase of 18% to $2.96B, Europe segment increase of 26% to $1.19B.

Equity composition

Common Stock $1 Par, 12/10, 350M auth., 117,100,000 issd. less 2,000 shs. in Treas. @ $102M. Insiders control 0.64%. 4/3/00,Company spun off from Baxter International. 05/10, 2-for-1 stock split. 12/15, 2-for-1 stock split.

Industry: Advanced Medical Equipment & Technology (NEC)

One Edwards Way
IRVINE
CALIFORNIA 92614
US

Income Statement

  • Annual
  • Quarterly

News

Global Currencies.

FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis

USD, GBP/USD, EUR/USD forecasts for the week ahead.

16:33, 27 January 2023
Businessman representing recessionary, stagflation or inflation economies with graphs of the stock market as a concept of raw material. Financial world crisis concept.

WTI, Gold, Silver – commodities weekly forecast for the week ahead

Strength to strength in the commodity space, however, topside exhaustion begins to creep in

13:53, 27 January 2023
Rising stock market chart on a trading board background.

S&P 500, Nasdaq, DAX 40, Hang Seng technical update

Can the S&P 500 hold above its 2022 descending trend line?

12:44, 26 January 2023
photo illustration an Amazon logo seen displayed on a smartphone.

Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending

AMZN Q4 earnings preview and technical analysis

09:59, 25 January 2023
Bank of Canada outlook

Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike

Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.

15:49, 24 January 2023

People also watch

US100

12,164.80 Price
+1.340% 1D Chg, %
Long position overnight fee -0.0179%
Short position overnight fee 0.0070%
Overnight fee time 22:00 (UTC)
Spread 3.0

Natural Gas

2.86 Price
+0.740% 1D Chg, %
Long position overnight fee -0.0485%
Short position overnight fee 0.0282%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

23,020.60 Price
-0.450% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

ETH/USD

1,589.11 Price
-0.810% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 5.00

Market analysis

A large Amazon logo displayed on the side of an Amazon building

Amazon stock forecast: Where next for AMZN amid massive layoffs?

17:55, 23 January 2023
Australian dollar bills

Australian dollar forecast: Will AUD outperform in 2023?

17:49, 20 January 2023
Dogecoin token on mobile phone screen

Dogecoin price prediction: DOGE to the moon?

17:43, 20 January 2023

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading